Inflammation Provenance
Simple: the microbiome, which is 2/3 of our immune system. If you want to cut back on rheumatologic problems or risk, feed your microbiome better. It will also lead to improved metabolic performance (read lose weight and chronic problems like diabetes, obesity and heart disease. And yes, even cancer and mood disorders.)
The article below highlights these concepts, albeit, focusing on GLP-1 drugs. That is fine, but remember people regain their weight if they do not stay on a plant-based anti-inflammatory diet.
Reference
Rheumatology enters the gut-brain-immune axis
Healio Minute, March 23, 2026
It is difficult to overstate the excitement surrounding this expanding field. At a minimum, these early observations hold the potential to reshape how we think about inflammation across a remarkably broad spectrum of rheumatic disease — from lupus and psoriatic arthritis to osteoarthritis, gout and beyond.
In this editorial, I would like to step beyond the early headlines and reflect on what I believe may represent a true frame shift for our specialty. Rheumatology has spent the past generation dissecting immune-mediated disorders through the lens of cytokines, immune cell subsets and molecular signaling pathways. This reductionist approach has yielded extraordinary therapeutic advances. Yet it is becoming increasingly clear that it is not sufficient.
A growing body of evidence supports what many of us have gradually come to recognize: The brain, gut and immune system function as an integrated physiologic network. If we are to fully understand IMIDs — and meaningfully transform outcomes for our patients — we must broaden our lens and actively engage with the rapidly emerging gut-brain-immune axis.
At first blush, it seemed intuitive that the anti-inflammatory effects of GLP-1 receptor agonists were largely mediated through metabolic improvements, including weight loss and reductions in visceral adiposity. However, accumulating evidence suggests that weight-independent mechanisms play a significant role. Reductions in circulating inflammatory markers such as IL-6, improvements in insulin resistance, and decreases in uric acid levels have all been observed in ways that cannot be fully explained by weight reduction alone.
Moreover, cardio-renal benefits have been demonstrated even in non-diabetic populations without significant weight loss, further supporting the concept that these agents exert biologic effects beyond adipose tissue modulation.
Even more intriguingly, emerging data suggest a substantial component of the anti-inflammatory effect may be mediated through central mechanisms. Rather than acting solely through peripheral immune cell receptor engagement, GLP-1 receptor activation within the central nervous system appears capable of modulating peripheral inflammation through neuroimmune pathways. As highlighted by Dr. Duker, one of our Healio Exclusive discussants, the gut-brain GLP-1 receptor axis may represent a novel and underappreciated pathway for systemic immune regulation, one that extends well beyond traditional models of immunocyte signaling and adipose-driven inflammation.
Perhaps the clearest signal that this shift is clinically relevant is the recent FDA approval of vagal nerve stimulation for treatment-refractory rheumatoid arthritis, as recently discussed in a Healio Exclusive accompanied by my editorial in Healio Rheumatology. Regardless of how one views this therapeutic approach — or how it will ultimately integrate into clinical practice — the implications are profound. The approval represents a formal recognition that neuroimmune circuitry is not merely an academic curiosity, but a legitimate therapeutic target in inflammatory disease.
More broadly, the growing appreciation of neuroimmune regulation, along with advances in placebo biology and mechanistic insights into autonomic modulation of inflammation, suggests that the future of immunology will require a far deeper understanding of the brain-immune axis. The implications for rheumatology are enormous, and the time has come for our field to fully engage.
Ultimately, this is not simply a story about GLP-1 therapies. It is a signal that our traditional boundaries in rheumatology are no longer sufficient. We have become extraordinarily skilled at mapping inflammatory pathways, yet we may have underestimated the role of the nervous system as an upstream regulator of immune behavior. The emerging science of the gut-brain-immune axis suggests that inflammation is not merely a molecular cascade. It is a biologic network, shaped by metabolism, autonomic tone, central signaling and environmental inputs. If we want to remain leaders in the care of IMIDs, we must widen our framework, deepen our neuroimmunologic literacy, and accept that the next generation of breakthroughs may come not only from the immune cell, but from the brain that orchestrates it.
